Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,527 across all filing types
Latest filing 2017-03-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding the use of funds by controlling shareholders and related parties, specifically for the fiscal year ending December 31, 2016. It references an audit report issued by Da Hua Certified Public Accountants with an unqualified opinion on the 2016 financial statements. The document includes detailed tables summarizing non-operating fund occupation and related party transactions. It is issued in compliance with regulations from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding disclosure of related party transactions and fund occupation. The document is a standalone audit-related explanatory report focusing on a specific issue (related party fund occupation) rather than a full annual report or financial statement. It is not a general annual report (10-K), nor a brief announcement or certification. It is a specialized audit report or information related to audit findings and regulatory compliance on related party transactions. Therefore, the most appropriate classification is Audit Report / Information (AR). FY 2016
2017-03-27 Chinese
2016年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as the "2016 Annual Report Summary" of 华兰生物工程股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2016, including revenue, net profit, earnings per share, and asset totals, as well as business descriptions and operational highlights. The presence of comprehensive financial figures and business overview aligns with the characteristics of an Annual Report (10-K). The document is about 15,000 characters long, which is consistent with a substantive report rather than a brief announcement. Therefore, this document should be classified as an Annual Report (10-K). FY 2016
2017-03-27 Chinese
独立董事2016年度述职报告（章金刚）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of a company for the year 2016. It includes the director's attendance at meetings, independent opinions on related party transactions, external guarantees, internal control evaluation, appointment of auditors, investment and financing matters, dividend proposals, and other governance-related activities. The content is focused on the independent director's duties and opinions regarding the company's governance and financial oversight for the year 2016. It is not a full annual report (10-K), nor is it an audit report or earnings release. It is a specific report by an independent director on their annual duties and opinions, which aligns with the category of Board/Management Information (MANG), as it relates to management and board-level disclosures and opinions. The document length (6010 characters) and detailed content support this classification rather than a brief announcement or regulatory filing.
2017-03-27 Chinese
独立董事2016年度述职报告（苏志国）
Board/Management Information Classification · 95% confidence The document is titled as an independent director's 2016 annual performance report for a company, detailing the director's attendance at meetings, independent opinions on various company matters including related party transactions, external guarantees, internal control evaluation, audit firm appointment, investment and financing, dividend proposals, and board candidate opinions. It references compliance with regulatory guidelines and laws, and includes detailed narrative and opinions rather than just announcements. The document length is over 6000 characters, indicating it is a substantive report rather than a brief announcement. The content focuses on the independent director's duties and opinions related to the company's governance and financial oversight for the year 2016. This fits the category of Board/Management Information (MANG), which includes announcements of changes or reports related to the company's board or senior management activities. It is not an Annual Report (10-K) or Audit Report (AR) because it is specifically an independent director's report, not a full financial or audit report. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains detailed content rather than just a notice or certification. Therefore, the best classification is MANG with high confidence.
2017-03-27 Chinese
2016年年度报告
Annual Report Classification · 100% confidence The document is titled as the 2016 Annual Report of 华兰生物工程股份有限公司 (Hualan Biological Engineering Inc.) and contains detailed sections typical of an annual report, including company overview, financial data, business summary, management discussion and analysis, governance, and financial statements. It includes comprehensive financial figures for the fiscal year 2016, detailed business operations, product descriptions, and strategic outlook. The document length is substantial (15,000 characters), and it is not a brief announcement or a certification. The content matches the definition of an Annual Report (10-K) as it covers the full financial performance and company activities for the year. Therefore, the correct classification is Annual Report (10-K). FY 2016
2017-03-27 Chinese
股东大会议事规则（2017年3月）
AGM Information Classification · 95% confidence The document is titled as the "Rules of Procedure for the Shareholders' General Meeting" of a company, detailing the organization, rights, procedures, and regulations governing the shareholders' meetings. It extensively covers the conduct, voting, proposals, and legal compliance related to shareholders' meetings. There is no financial data, earnings information, or audit content. It is not a report of financial results or management discussion but a governance document related to shareholder meetings. This fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or related procedural rules.
2017-03-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.